3933 — United Laboratories International Holdings Balance Sheet
0.000.00%
- HK$14.97bn
- HK$12.02bn
- CNY13.74bn
- 97
- 74
- 97
- 100
Annual balance sheet for United Laboratories International Holdings, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 3,165 | 2,997 | 3,331 | 4,743 | 4,262 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 3,241 | 3,359 | 3,800 | 4,912 | 6,314 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 8,714 | 8,225 | 9,986 | 12,515 | 13,787 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 6,487 | 6,389 | 6,131 | 6,266 | 7,004 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 15,700 | 14,964 | 16,331 | 18,980 | 21,017 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 6,459 | 4,860 | 6,535 | 7,033 | 6,627 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 9,028 | 6,350 | 6,991 | 8,372 | 8,282 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 6,672 | 8,614 | 9,340 | 10,608 | 12,735 |
Total Liabilities & Shareholders' Equity | 15,700 | 14,964 | 16,331 | 18,980 | 21,017 |
Total Common Shares Outstanding |